GET DAILY SIGNALSWhy Is Nutex Health (NUTX) Stock Down -5.53% Today?
Key Takeaways
- Shares fell 5.53% intraday, with NUTX trading near $182.93 versus a prior-session close of $193.64.
- Primary catalyst: A negative market reaction to the company's third-quarter 2026 results, which showed sharp year-over-year declines in revenue and profit.
- Secondary drivers: A roughly 35% drop in adjusted EBITDA and an unfavorable base-effect comparison to a strong 2025 period.
- Broader context: The decline reflects company-specific fundamentals rather than broad healthcare-sector weakness.
- What traders are watching next: Management's outlook on its conference call and the planned opening of two new hospitals in the fourth quarter.
- For more on this stock's outlook, explore Price Targets, Earnings, and Forecast pages for NUTX.
- To discover AI-driven trading strategies actively outperforming in current markets, explore Trending AI Robots.
Opening Summary
Nutex Health Inc. (NUTX), a physician-led healthcare services and operations company that owns and operates 28 hospital facilities across 12 states alongside a population health management division, saw its shares trade lower on Thursday. The stock was down roughly 5.53%, changing hands near $182.93 after closing the previous session at $193.64. The selling pressure extended a pullback that began when the Houston-based company reported its third-quarter 2026 financial results, which markets read as disappointing despite mixed headline figures versus analyst estimates.
Earnings-Driven Decline
The primary catalyst behind the move was the company's third-quarter report. Total revenue fell 18.7% year over year to approximately $217.6 million, while net income attributable to Nutex Health declined about 27.4% to $40.2 million. Diluted earnings per share came in at $5.71, down from $7.76 in the prior-year quarter. Adjusted EBITDA attributable to the company dropped roughly 35% to $63.9 million, compared with $98.5 million a year earlier.
Management attributed the decline largely to factors that had favorably boosted 2025 revenue, including additional collection data supporting higher estimates for services rendered in 2024 and the reconciliation of certain ineligible charts during late 2025. These one-time-friendly comparisons created a difficult base effect for the current period, and the market reaction suggests investors are focused on the shrinking profitability trend rather than the year-to-date improvement in cumulative results.
Mixed Estimates and a Cautious Tone
Although the quarter produced mixed results relative to Wall Street consensus — with revenue coming in slightly above some forecasts while earnings per share landed below others — the broader narrative of declining margins and a lower adjusted EBITDA weighed on sentiment. Even as patient volumes grew 18.1% year over year, driven by both new and same-hospital growth, the reduced profitability per visit reinforced concerns about reimbursement dynamics and cost pressures in the micro-hospital model.
Market Context and Trading Activity
The decline in NUTX appears to be a company-specific, earnings-driven move rather than a reflection of a broader healthcare selloff. The stock's pullback continued into Thursday's session following its earnings release, suggesting investors were still digesting the results ahead of the company's scheduled conference call. Trading activity has been elevated around the report, consistent with heightened investor attention to a stock that has experienced substantial volatility in recent months.
What Comes Next for NUTX
Looking ahead, investors will focus on management's commentary regarding the fourth quarter and the anticipated opening of two new hospitals before year-end. Key watchpoints include the trajectory of same-hospital revenue, the performance of the population health management division, and any updates on the arbitration process under the No Surprises Act. Risks and uncertainties include regulatory and litigation exposure, cybersecurity-related matters, and the potential for continued unfavorable year-over-year comparisons in the near term. The company's next quarterly report and its guidance for the coming fiscal year will be critical in determining whether the current pullback represents a buying opportunity or the start of a more sustained repricing.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently among the strongest performers under live market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the top performers are featured in the Trending AI Robots section, providing a focused view of strategies that are working right now. Explore Trending AI Robots to see which automated strategies are gaining momentum in today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NUTX in downward trend: 10-day moving average broke below 50-day moving average on November 03, 2026
The 10-day moving average for NUTX crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUTX as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for NUTX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
NUTX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NUTX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NUTX's RSI Oscillator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 59 cases where NUTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUTX advanced for three days, in 218 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
NUTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. NUTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.136) is normal, around the industry mean (203.977). P/E Ratio (6.740) is within average values for comparable stocks, (20.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.097) among similar stocks. P/S Ratio (1.830) is also within normal values, averaging (2.688).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement